Cybin Completes Enrollment in Phase 2 Study for GAD Treatment

Cybin ( (TSE:CYBN) ) has provided an update.

Cybin has completed enrollment in its Phase 2 study evaluating CYB004 for treating Generalized Anxiety Disorder (GAD), enrolling 36 participants to assess safety and efficacy. This milestone highlights CYB004’s potential as a convenient intramuscular treatment for GAD, addressing a significant unmet need as many patients do not respond to existing therapies. The study’s results, expected in Q1 2026, could impact Cybin’s positioning in the mental health treatment landscape.

The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$39.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.

Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.

To see Spark’s full report on TSE:CYBN stock, click here.

More about Cybin

Cybin is a late-stage breakthrough neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is working on novel drugs to address unmet needs in mental health, with operations in Canada, the United States, the United Kingdom, and Ireland. Cybin is currently advancing CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.

Technical Sentiment Signal: Hold

Current Market Cap: C$1.97M

For detailed information about CYBN stock, go to TipRanks’ Stock Analysis page.